| 1 |
Pieracci FM,，Barie PS.Management of severe sepsis of abdominal origin[J]．Scand J Surg，2007，96(3)：184-196.
|
| 2 |
Rhodes A,，Evans LE,，Alhazzani W，et al.Surviving sepsis campaign：international guidelines for management of sepsis and septic shock：2016[J]．Intensive Care Med，2017，43(3)：486-552.
|
| 3 |
Vincent JL,，Rello J,，Marshall J，et al.International study of the prevalence and outcomes of infection in intensive care units[J]．JAMA，2009，302(21)：2323-2329.
|
| 4 |
Mazuski JE,，Tessier JM,，May AK，et al.The surgical infection society revised guidelines on the management of intra-abdominal infection[J]．Surg Infect(Larchmt)，2017，18(1)：1-76.
|
| 5 |
任建安，黎介寿．严重腹腔感染的综合治疗[J]．中国实用外科杂志，2007，27(12)：940-942.
|
| 6 |
Bassetti M,，Poulakou G,，Ruppe E，et al.Antimicrobial resistance in the next 30 years, humankind，bugs and drugs：a visionary approach[J]．Intensive Care Med，2017，43(10)：1464-1475.
|
| 7 |
Tacconelli E,，Carrara E,，Savoldi A，et al.Discovery，research，and development of new antibiotics：the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]．Lancet Infect Dis，2018，18(3)：318-327.
|
| 8 |
Karaiskos I,，Giamarellou H．Multidrug-resistant and extensively drug-resistant gram-negative pathogens：current and emerging therapeutic approaches[J]．Expert Opin Pharmacother，2014，15(10)：1351-1370.
|
| 9 |
Menichetti F,，Sganga G．Definition and classification of intra-abdominal infections[J]．J Chemother，2009，21 (Suppl 1)：3-4.
|
| 10 |
Lorber B,，Swenson RM.The bacteriology of intra-abdominal infections[J]．Surg Clin North Am，1975，55(6)：1349-1354.
|
| 11 |
Weigelt JA.Empiric treatment options in the management of complicated intra-abdominal infections[J]．Cleve Clin J Med，2007，74 (Suppl 4)：S29-S37.
|
| 12 |
Farthmann EH,，Schöffel U．Epidemiology and pathophysiology of intraabdominal infections (IAI)[J]．Infection，1998，26(5)：329-334.
|
| 13 |
Liu Q,，Ren J,，Wu X，et al.Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China：an eight-year review in a tertiary-care hospital[J]．BMC Infect Dis，2017，17(1)：637.
|
| 14 |
Sartelli M,，Chichom-Mefire A,，Labricciosa FM，et al.The management of intra-abdominal infections from a global perspective：2017 WSES guidelines for management of intra-abdominal infections[J]．World J Emerg Surg，2017(12)：29.
|
| 15 |
Morrissey I,，Hackel M,，Badal R，et al.A review of ten years of the study for monitoring antimicrobial resistance trends(SMART)from 2002 to 2011[J]．Pharmaceuticals(Basel)，2013，6(11)：1335-1346.
|
| 16 |
胡付品，郭燕，朱德妹，等.2016年中国CHINET细菌耐药性监测[J]．中国感染与化疗杂志，2017，17(5)：481-491.
|
| 17 |
Huang CC,，Chen YS,，Toh HS，et al.Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among enterobacteriaceae isolates in the asia-pacific region：results from the study for monitoring antimicrobial resistance trends (SMART)，2002-2010[J]．Int J Antimicrob Agents，2012(40 Suppl)：S4-S10.
|
| 18 |
国家卫生健康委合理用药专家委员会，全国细菌耐药监测网. 2019年全国细菌耐药监测报告[J]. 中国合理用药探索，2021，18(3)：1-11.
|
| 19 |
Ruppé é,，Woerther PL,，Barbier F．Mechanisms of antimicrobial resistance in gram-negative bacilli[J]．Ann Intensive Care，2015，5(1)：61.
|
| 20 |
Zhang H,，Yang Q,，Liao K，et al.Update of incidence and antimicrobial susceptibility trends of escherichia coli and klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients[J]．BMC Infect Dis，2017，17(1)：776.
|
| 21 |
Alekshun MN,，Levy SB.Molecular mechanisms of antibacterial multidrug resistance[J]．Cell，2007，128(6)：1037-1050.
|
| 22 |
Sheng W-H,，Badal RE,，Hsueh PR.Distribution of extended-spectrum β-lactamases，ampc β-lactamases，and carbapenemases among enterobacteriaceae isolates causing intra-abdominal infections in the asia-pacific region：results of the study for monitoring antimicrobial resistance trends(SMART)[J]．Antimicrob Agents Chemother，2013，57(7)：2981-2988.
|
| 23 |
Hansen DS,，Gottschau A,，Kolmos HJ.Epidemiology of klebsiella bacteraemia：a case control study using escherichia coli bacteraemia as control[J]．J Hosp Infect，1998，38(2)：119-132.
|
| 24 |
CHINET数据云．肺炎克雷伯菌对亚胺培南和美罗培南的耐药变迁[EB/OL]．(2021-09-27)[2021-09-27]．
URL
|
| 25 |
Grundmann H,，Glasner C,，Albiger B，et al.Occurrence of carbapenemase-producing klebsiella pneumoniae and escherichia coli in the european survey of carbapenemase-producing enterobacteriaceae(EuSCAPE)：a prospective，multinational study[J]．Lancet Infect Dis，2017，17(2)：153-163.
|
| 26 |
Doi Y,，Bonomo RA,，Hooper DC，et al.Gram-negative bacterial infections：research priorities，accomplishments，and future directions of the antibacterial resistance leadership group[J]．Clin Infect Dis，2017，64(Suppl_1)：S30-S35.
|
| 27 |
Pitout JD,，Nordmann P,，Poirel L．Carbapenemase-producing klebsiella pneumoniae，a key pathogen set for global nosocomial dominance[J]．Antimicrob Agents Chemother，2015，59(10)：5873-5884.
|
| 28 |
Xu L,，Sun X,，Ma X．Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant klebsiella pneumoniae[J]．Ann Clin Microbiol Antimicrob，2017，16(1)：18.
|
| 29 |
Tumbarello M,，Trecarichi EM,，De Rosa FG，et al.Infections caused by KPC-producing klebsiella pneumoniae：differences in therapy and mortality in a multicentre study[J]．J Antimicrob Chemother，2015，70(7)：2133-2143.
|
| 30 |
Liu YC,，Cheng DL,，Lin CL.Klebsiella pneumoniae liver abscess associated with septic endophthalmitis[J]．Arch Intern Med，1986，146(10)：1913-1916.
|
| 31 |
Sellick JA,，Russo TA.Getting hypervirulent klebsiella pneumoniae on the radar screen[J]．Curr Opin Infect Dis，2018，31(4)：341-346.
|
| 32 |
Blin C,，Passet V,，Touchon M，et al.Metabolic diversity of the emerging pathogenic lineages of klebsiella pneumoniae[J]．Environ Microbiol，2017，19(5)：1881-1898.
|
| 33 |
Yang Q,，Wang H,，Chen M，et al.Surveillance of antimicrobial susceptibility of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections in China：the 2002-2009 study for monitoring antimicrobial resistance trends(SMART)[J]．Int J Antimicrob Agents，2010，36(6)：507-512.
|
| 34 |
Tacconelli E,，Cataldo MA,，Dancer SJ，et al.ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients[J]．Clin Microbiol Infect，2014(20 Suppl 1)：1-55.
|
| 35 |
Dima S,，Kritsotakis EI,，Roumbelaki M，et al.Device-associated nosocomial infection rates in intensive care units in greece[J]．Infect Control Hosp Epidemiol，2007，28(5)：602-605.
|
| 36 |
Fournier PE,，Richet H．The epidemiology and control of acinetobacter baumannii in health care facilities[J]．Clin Infect Dis，2006，42(5)：692-699.
|
| 37 |
Lolans K,，Rice TW,，Munoz-Price LS，et al.Multicity outbreak of carbapenem-resistant acinetobacter baumannii isolates producing the carbapenemase OXA-40[J]．Antimicrob Agents Chemother，2006，50(9)：2941-2945.
|
| 38 |
Talbot GH,，Bradley J,，Edwards JE Jr，et al.Bad bugs need drugs：an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of america[J]．Clin Infect Dis，2006，42(5)：657-668.
|
| 39 |
Getchell-White SI,，Donowitz LG,，Gröschel DH.The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria：evidence for long survival of acinetobacter calcoaceticus[J]．Infect Control Hosp Epidemiol，1989，10(9)：402-407.
|
| 40 |
Munoz-Price LS,，Weinstein RA.Acinetobacter infection[J]．N Engl J Med，2008，358(12)：1271-1281.
|
| 41 |
Fournier PE,，Vallenet D,，Barbe V，et al.Comparative genomics of multidrug resistance in Acinetobacter baumannii[J]．PLoS Genet，2006，2(1)：e7.
|
| 42 |
Garnacho-Montero J,，Ortiz-Leyba C,，Fernández-Hinojosa E，et al.Acinetobacter baumannii ventilator-associated pneumonia：epidemiological and clinical findings[J]．Intensive Care Med，2005，31(5)：649-655.
|
| 43 |
Manikal VM,，Landman D,，Saurina G，et al.Endemic carbapenem-resistant acinetobacter species in brooklyn，New York：citywide prevalence，interinstitutional spread，and relation to antibiotic usage[J]．Clin Infect Dis，2000，31(1)：101-106.
|
| 44 |
Maragakis LL,，Cosgrove SE,，Song X，et al.An outbreak of multidrug-resistant acinetobacter baumannii associated with pulsatile lavage wound treatment[J]．JAMA，2004，292(24)：3006-3011.
|
| 45 |
Subedi D,，Vijay AK,，Willcox M．Overview of mechanisms of antibiotic resistance in pseudomonas aeruginosa：an ocular perspective[J]．Clin Exp Optom，2018，101(2)：162-171.
|
| 46 |
Peña C,，Gómez-Zorrilla S,，Suarez C，et al.Extensively drug-resistant pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients[J]．Eur J Clin Microbiol Infect Dis，2012，31(10)：2791-2797.
|
| 47 |
Chinese XDR Consensus Working Group，Guan X,，He L，et al.Laboratory diagnosis，clinical management and infection control of the infections caused by extensively drug-resistant gram-negative bacilli：a Chinese consensus statement[J]．Clin Microbiol Infect，2016(22 Suppl 1)：S15-S25.
|
| 48 |
Magill SS,，Edwards JR,，Bamberg W，et al.Multistate point-prevalence survey of health care-associated infections[J]．N Engl J Med，2014，370(13)：1198-1208.
|
| 49 |
Magiorakos AP,，Srinivasan A,，Carey RB，et al.Multidrug-resistant，extensively drug-resistant and pandrug-resistant bacteria：an international expert proposal for interim standard definitions for acquired resistance[J]．Clin Microbiol Infect，2012，18(3)：268-281.
|
| 50 |
Kollef MH,，Bassetti M,，Francois B，et al.The intensive care medicine research agenda on multidrug-resistant bacteria，antibiotics，and stewardship[J]．Intensive Care Med，2017，43(9)：1187-1197.
|
| 51 |
Karaiskos I,，Antoniadou A,，Giamarellou H．Combination therapy for extensively-drug resistant gram-negative bacteria[J]．Expert Rev Anti Infect Ther，2017，15(12)：1123-1140.
|
| 52 |
Paul M,，Daikos GL,，Durante-Mangoni E，et al.Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label，randomised controlled trial[J]．Lancet Infect Dis，2018，18(4)：391-400.
|
| 53 |
Evans L,，Rhodes A,，Alhazzani W，et al.Surviving sepsis campaign：international guidelines for management of sepsis and septic shock 2021[J]．Intensive Care Med，2021，47(11)：1181-1247.
|
| 54 |
Sawyer RG,，Claridge JA,，Nathens AB，et al.Trial of short-course antimicrobial therapy for intraabdominal infection[J]．N Engl J Med，2015，372(21)：1996-2005.
|
| 55 |
Montravers P,，Tubach F,，Lescot T，et al.Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection：the DURAPOP randomised clinical trial[J]．Intensive Care Med，2018，44(3)：300-310.
|
| 56 |
Tacconelli E,，Mazzaferri F,，de Smet AM，et al.ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant gram-negative bacteria carriers[J]．Clin Microbiol Infect，2019，25(7)：807-817.
|